We observed several cases of hypotension associated with high-dose dacarbazine. We conducted a retrospective observational analysis of all patients treated with high-dose dacarbazine from January 2018 to August 2019 in Oscar Lambret Center, Lille, France. In our study, a total of 23 patients in outpatient care were analyzed, they underwent 57 treatment cycles. https://www.selleckchem.com/products/3po.html We observed 8 episodes of hypotension in 7 of the 23 consecutive treated patients (30.4%). We discuss herein several hypotheses explaining dacarbazine-induced hypotension. Dacarbazine high dose and administration methods seem to be the main causes of hypotension adverse events. Administration methods include administration duration, which should be above 2 hours, concomitant hydration with 500?ml 0.9% sodium chloride, and UV-resistant pump tube downstream the administration tree.Immune checkpoint inhibitors have become the mainstay of treatment for metastatic melanoma. This article presents a new case of acquired generalised lipodystrophy (AGL) during anti-programmed cell death-1 (anti-PD-1) therapy and a systematic review of the literature with an aim to further understand the pathogenesis. A comprehensive search was conducted using PubMed, Embase, MEDLINE and Cochrane Central databases. We identified four cases of lipodystrophy associated with anti-PD-1 immunotherapy, including our own. Of these, three were associated with nivolumab, and one with pembrolizumab. Body composition changes occurred at a median of 7 months after anti-PD-1 initiation. All cases reported AGL, with subcutaneous fat loss affecting majority of the body. There were three reported cases of insulin resistance associated with AGL. AGL should be a recognised adverse event associated with anti-PD-1 therapy.Artificial intelligence (AI) is a broad field of computational science that includes many subsets. Today the most widely used subset in medical imaging is machine learning (ML). Many articles have focused on the use of ML for pattern recognition to detect and potentially diagnose various pathologies. However, AI algorithm development is now directed toward workflow management. AI can impact patient care at multiple stages of their imaging experience and assist in efficient and effective scheduling, imaging performance, worklist prioritization, image interpretation, and quality assurance. The purpose of this manuscript was to review the potential AI applications in radiology focusing on workflow management and discuss how ML will affect cardiothoracic imaging.BACKGROUND Adherence to antiretroviral therapy (ART) is imperative for viral suppression and reducing HIV transmission, but many people living with HIV report difficultly sustaining long-term adherence. Long-acting injectable (LAI) ART has the potential to transform HIV treatment and prevention. However, little LAI ART-related behavioral research has occurred among women, particularly outside of clinical trials. SETTING Six Women's Interagency HIV Study (WIHS) sites New York, Chicago, Washington DC, Atlanta, Chapel Hill, and San Francisco. METHODS We conducted 59 in-depth interviews with women living with HIV across six WIHS sites (10 per site; 9 at Washington DC). We interviewed women were who were not included in LAI ART clinical trials, but who receive care at university settings that will administer LAI ART once it is approved. Interviews were recorded, transcribed, and analyzed using thematic content analysis. RESULTS Most women enthusiastically endorsed monthly LAI ART and would prefer it over pills. Three reasons emerged for this preference 1) convenience and confidentiality; 2) avoiding daily reminders about living with HIV; and 3) believing that shots are more effective than pills. Challenges remain, however, specifically around 1) medical mistrust; 2) concerns about safety and effectiveness; 3) pill burden for HIV and other conditions; and 4) barriers to additional medical visits. CONCLUSION Most women preferred LAI ART over daily pills given its benefits including convenience, privacy, and perceived effectiveness. Future research should incorporate more women into LAI ART trials in order to better understand and align development with user concerns and preferences in order to enhance uptake.BACKGROUND Reduced bone mineral mass by dual x-ray absorptiometry (DXA) is reported in children living with HIV (CLWH), but few studies of bone microarchitecture, particularly in sub-Saharan Africa, have been conducted. Here, we compare bone architecture and strength in black South African CLWH and uninfected control children by peripheral quantitative computed tomography (pQCT). SETTING and Methods 172 CLWH on antiretroviral therapy (ART) and 98 controls in the CHANGES Bone Study in Johannesburg, South Africa received pQCT scans of the radius and tibia. Measurements included trabecular and cortical volumetric BMD (vBMD) and bone strength, estimated by the polar strength strain index (SSI), a validated measure of fracture risk. RESULTS CLWH (51% male) and controls (63% male) were an average of 10.4 years of age. Mean ART duration for CLWH was 9.5 years, with 70.9% on an efavirenz-based, 28.5% on a lopinavir/ritonavir-based, and 1 child on an atazanavir/ritonavir-based regimen. Male CLWH had lower trabecular vBMD at the radius than controls after adjustment for age, radial length, and Tanner stage (β=-17.3, SE=7.2, p=0.018). Bone strength by polar SSI was lower in CLWH than controls (778 vs. 972 mm, p less then 0.01). CLWH on a LPV/r-based regimen had lower trabecular vBMD (199 vs. 222 mg/cm, p less then 0.001) and cortical vBMD (1074 vs. 1093 mg/cm, p=0.004) than those on an efavirenz-based regimen. No difference in bone strength by polar SSI was observed between treatment groups. CONCLUSION CLWH initiated on ART early in life with well-controlled HIV have deficits in bone architecture and reductions in bone strength as detected by pQCT.INTRODUCTION Heterosexual men are not considered a key population in the HIV response and are mostly absent from pre-exposure prophylaxis (PrEP) studies to-date. Yet South African men face considerable HIV risk. We estimate the incremental cost-effectiveness of providing oral PrEP, injectable PrEP, or a combination of both to heterosexual South African men to assess if providing PrEP would efficiently use resources. METHODS Epidemiological and costing models estimated the one-year costs and outcomes associated with PrEP use in three scenarios. PrEP uptake was estimated for younger (aged 18-24) and older (aged 25-49) men using a discrete choice experiment. Scenarios were compared to a baseline scenario of male condom use, while a health system perspective was used to estimate discounted lifetime costs averted per HIV infection. PrEP benefit was estimated in disability-adjusted life years (DALYs) averted. Uncertainty around the estimated incremental cost-effectiveness ratios (ICERs) were assessed using deterministic and probabilistic sensitivity analyses.